30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
- Poster presentation
- Open Access
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy
Journal for ImmunoTherapy of Cancer volume 3, Article number: P53 (2015)
Strategies that enhance the function of T cells are critical for immunotherapy.
Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of PD-1.
We showed that the gene knockout of PD-1 by electroporation of plasmids encoding sgRNA and Cas9 was technically feasible. The disruption of PD-1 resulted in significant reduction of PD-1 expression but didn't affect the viability of primary human T cells. Cellular immune response of the gene modified T cells was characterized by up-regulated IFN-γ production and enhanced cytotoxicity.
These results suggest that we have established an approach for efficient checkpoint inhibitor disruption, providing a new strategy for targeting checkpoint inhibitors to improve the efficacy of T cell based adoptive therapies.
Topalian SL, Hodi S, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012, 366: 2443-2454.
Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, et al: Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014, 21 (3): 262-271.
Lloyd A, Vickery ON, Laugel B: Beyond the antigen receptor: editing the genome of T cells for cancer adoptive cellular therapies. Front Immunol. 2013, 4: 221-
Li W, Teng F, Li T, Zhou Q: Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol. 2013, 31 (8): 684-686.
Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al: Generation of gene- modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 2013, 23: 720-723.
Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al: Generation of gene-modified Cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014, 156 (4): 1-8.
Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al: Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014, 11 (4): 399-402.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2014, 366 (26): 2443-2454.
Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, et al: siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T cell effector functions. Gene Therapy. 2012, 19 (10): 959-966.
Chicaybam L, Sodre AL, Curzio BA, Bonamino MH: An efficient low cost method for gene transfer to T lymphocytes. PLOS One. 2013, 8: e60298-
The authors thank the entire Huang Lab and Liu Lab for their support and advice. This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81172281, 81000980, 81220108023, 81172094).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Su, S., Liu, B. & Zou, Z. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy. j. immunotherapy cancer 3 (Suppl 2), P53 (2015). https://doi.org/10.1186/2051-1426-3-S2-P53
- Public Health
- Immune Response
- Cellular Immune Response
- Gene Knockout
- Mediate Approach